Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

No BS RX vs PCOS Sisters

By GLP-1 ScorecardUpdated

No BS RXFactor scores not reassessed.
Site position #23

Higher score

PCOS SistersFactor scores not reassessed.
Site position #226

Lower score

Score comparison

No BS RX has the higher recorded score — 82.8/100 to 66/100.

No BS RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. No BS RX publishes separate prices for standard compounded, low-dose and brand-name programs.

Before you choose

PCOS Sisters does not publish a semaglutide price, so its PCOS Sisters review sets out what it does disclose, while the No BS RX review explains the conditions attached to No BS RX's figure. The semaglutide cost page compares published rates across the field. Ask PCOS Sisters for a written total before treating either one as the cheaper choice.

If neither one fits, No BS RX vs PreventiveMD and PCOS Sisters vs Sesame Care compare each of them with another graded program, and the list of alternatives to No BS RX ranks the programs closest to No BS RX on price, features and score. Those pages, like every entry in the review directory, use the same six graded factors, so the scores carry across.

Of the sellers that pay us a commission, the Belle Health review covers one graded close to these two, at 73.8/100. That relationship never changes a grade, and the review lists what we could not verify.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueNo BS RX +30
92
62
Dose & formulationNo BS RX +2
90
88
Clinical oversightNo BS RX +2
72
70
Labs & monitoringNo BS RX +16
68
52
FulfillmentNo BS RX +29
94
65
Contract termsNo BS RX +33
74
41
No BS RX · top barPCOS Sisters · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricNo BS RXPCOS Sisters
WeighScore82.8/10066/100
GradeB−C
Site position#23#226
Semaglutide$149/mo advertised for standard compounded injection; low-dose priced separatelyMedication price not confirmed; active membership required
Tirzepatide$225/mo advertised for standard compounded injection; low-dose priced separatelyMedication price not confirmed; active membership required
CoverageConfirm program availability for your stateConfirm your provider serves your state
Brand-name accessYesYes
Oral / sublingualYesYes
No BS RX

Site position #23 · B−

Factor scores not reassessed.

Strengths

  • Displays monthly and prepaid amounts by program
  • Advertises consultation, medication, shipping and messaging in the compounded plans
  • Lists branded Ozempic and Zepbound separately

What to consider

  • The $115 headline applies to low-dose programs
  • Plans renew automatically at the then-current rate
  • Cancellation generally stops future billing without refunding the current period
PCOS Sisters

Site position #226 · C

Factor scores not reassessed.

Strengths

  • Publishes a one-time evaluation fee and membership terms
  • Lists pharmacy partners on the weight-loss service page

What to consider

  • GLP-1 management requires active membership
  • Public fees do not establish an individual medication total
  • Prepaid memberships are described as nonrefundable

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Prices and terms can change; confirm them with the provider. Our factor scores may reflect earlier assessments; see our methodology. Not medical advice; see our disclosure.

← Back to the scorecard